What Is Bremelanotide? Uses, Benefits, Safety, FDA Status, and Evidence
Medical review note: This article is for educational purposes only and does not provide medical advice. Bremelanotide is an FDA-approved prescription medication for a specific use under the brand name Vyleesi. Unapproved bremelanotide or PT-141 products sold online are not the same as FDA-approved Vyleesi and may carry safety, quality, and legal risks.
Quick answer
Bremelanotide is a melanocortin receptor agonist sold under the brand name Vyleesi. It is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder, also called HSDD, when low sexual desire causes marked distress or interpersonal difficulty and is not caused by a medical condition, psychiatric condition, relationship problem, or medication. Bremelanotide is not indicated for postmenopausal women, men, or sexual performance enhancement. Clinical trials show statistically significant improvements in sexual desire and related distress, but benefits are modest, and the drug can cause nausea, flushing, injection-site reactions, headache, temporary blood-pressure increases, heart-rate reductions, and focal skin or gum darkening.
Key facts about Bremelanotide
| Question | Answer |
|---|---|
| What is bremelanotide? | A melanocortin receptor agonist peptide used in the FDA-approved drug Vyleesi. |
| Other names | Vyleesi, PT-141, bremelanotide acetate. |
| Drug class | Melanocortin receptor agonist. |
| Main mechanism | Activates melanocortin receptors involved in central nervous system pathways related to sexual desire. |
| FDA-approved? | Yes, as Vyleesi for a specific HSDD indication. |
| Approved use | Acquired, generalized HSDD in premenopausal women. |
| Not indicated for | Postmenopausal women, men, or sexual performance enhancement. |
| Human evidence level | Moderate human evidence for the approved HSDD indication. |
| Common side effects | Nausea, flushing, injection-site reactions, headache, vomiting, cough, fatigue, hot flashes, dizziness, and nasal congestion. |
| Main safety concern | Temporary blood-pressure increase, heart-rate reduction, nausea, focal hyperpigmentation, and use in the wrong population. |
| Sports status | Not identified here as specifically prohibited by name, but athletes should check Global DRO and current WADA rules before use. |
What is bremelanotide?
Bremelanotide is a prescription peptide medication and melanocortin receptor agonist. It is sold as Vyleesi, a subcutaneous injection approved by the FDA for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder.
The FDA-approved Vyleesi prescribing information states that Vyleesi is indicated for premenopausal women with acquired, generalized HSDD, where low sexual desire causes marked distress or interpersonal difficulty and is not due to a medical or psychiatric condition, relationship problems, or medication or drug effects.
Bremelanotide is also commonly known online as PT-141. That matters because many online peptide sellers use the name PT-141 for research-use products. Those products should not be treated as equivalent to FDA-approved Vyleesi.
How does bremelanotide work?
Bremelanotide activates melanocortin receptors. The FDA label describes it as a melanocortin receptor agonist that nonselectively activates several receptor subtypes, including MC1R, MC4R, MC3R, MC5R, and MC2R.
In plain English:
Bremelanotide is thought to act through brain pathways involved in sexual desire, rather than working like drugs that directly increase blood flow.
That distinction is important. Bremelanotide is not simply “female Viagra.” Viagra-like drugs primarily affect blood flow. Bremelanotide is used for desire-related symptoms in a specific HSDD population.
Mechanism is not the same as broad benefit. The FDA-approved use is narrow, and online claims that PT-141 improves libido, performance, erectile function, or general sexual health in all users go beyond the approved indication.
What is bremelanotide used for?
Bremelanotide has one main FDA-approved use and many broader online claims. These should not be treated the same.
| Use | Evidence level | What is known | What is not known |
|---|---|---|---|
| Acquired, generalized HSDD in premenopausal women | Moderate human evidence | Vyleesi is FDA-approved for this specific group. | Benefit size may be modest, and not all patients respond. |
| Postmenopausal HSDD | Not indicated | The FDA label says Vyleesi is not indicated for postmenopausal women. | Safety and efficacy for this group are not established under the Vyleesi indication. |
| Use in men | Not indicated | The FDA label says Vyleesi is not indicated for men. | Online PT-141 claims for men are not the same as FDA-approved use. |
| Sexual performance enhancement | Not indicated | The label explicitly says Vyleesi is not indicated to enhance sexual performance. | Performance claims are not supported by the approved indication. |
| Erectile dysfunction | Not FDA-approved for this use | Earlier investigational work explored sexual dysfunction, but Vyleesi is not approved for ED. | It should not be treated as an approved ED medication. |
| Online PT-141 products | High uncertainty | Sellers often market PT-141 as a peptide product. | Quality, sterility, dosing, and authenticity may be unknown. |
What does the research show?
Human evidence for HSDD
The main clinical evidence for bremelanotide comes from two 24-week phase 3 trials in premenopausal women with HSDD.
A PubMed-indexed phase 3 trial publication reported that bremelanotide significantly improved sexual desire and related distress in premenopausal women with HSDD.
The FDA label also describes the two clinical studies and notes that the co-primary endpoints involved change in sexual desire and distress scores. Importantly, the FDA label says there was no significant difference between treatment groups in the change in the number of satisfying sexual events, which was a secondary endpoint.
The practical interpretation:
Bremelanotide has human clinical evidence for sexual desire and distress outcomes in the approved HSDD population, but it should not be marketed as a universal sexual performance enhancer.
Human evidence for long-term use
A PubMed-indexed long-term safety and efficacy study reported sustained improvements in HSDD symptoms among premenopausal women treated with bremelanotide in an open-label extension.
That evidence is useful, but open-label extension data is not the same as blinded placebo-controlled evidence. It can help assess longer-term tolerability and durability, but it is more vulnerable to bias than randomized blinded trials.
Critical appraisal of benefits
Not every analysis is equally enthusiastic.
A 2024 PubMed-indexed review argued that bremelanotide’s benefits are statistically modest and limited to outcomes where the authors questioned the strength or validity of the evidence base.
That criticism does not mean bremelanotide “does not work.” It means a serious article should avoid hype. The fair conclusion is:
Bremelanotide is FDA-approved and has positive trial data for a narrow population, but its real-world benefit may be modest and should be weighed against side effects and patient-specific factors.
Evidence summary
| Claim | Evidence verdict | Explanation |
|---|---|---|
| “Bremelanotide treats HSDD in premenopausal women.” | Supported | Vyleesi is FDA-approved for acquired, generalized HSDD in premenopausal women. |
| “Bremelanotide increases sexual desire.” | Supported for approved population | Phase 3 trials showed improvements in desire-related endpoints. |
| “Bremelanotide improves sexual performance.” | Unsupported as an approved claim | FDA label says Vyleesi is not indicated to enhance sexual performance. |
| “Bremelanotide is for men.” | Not supported by FDA indication | Vyleesi is not indicated for men. |
| “Bremelanotide is for postmenopausal women.” | Not supported by FDA indication | Vyleesi is not indicated for postmenopausal women. |
| “Bremelanotide is the same as PT-141 from peptide vendors.” | Misleading | PT-141 is a synonym, but online research-use products are not the same as FDA-approved Vyleesi. |
| “Bremelanotide has no side effects.” | False | Nausea, flushing, injection-site reactions, headache, blood-pressure changes, and hyperpigmentation are known concerns. |
| “Bremelanotide is female Viagra.” | Misleading | It acts through melanocortin pathways related to desire, not primarily through blood-flow mechanisms like sildenafil. |
Is bremelanotide FDA-approved?
Yes. Bremelanotide is FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women.
The FDA approval package for Vyleesi identifies Vyleesi as bremelanotide subcutaneous injection and lists the approval date as June 21, 2019.
The key distinction:
Bremelanotide is FDA-approved when used as Vyleesi for the approved indication. Online PT-141 or bremelanotide peptide products are not the same as FDA-approved Vyleesi.
Is bremelanotide legal?
Bremelanotide is legal when prescribed and dispensed as the FDA-approved medication Vyleesi for appropriate medical use.
The problem is the online peptide market.
Many sellers market PT-141 or bremelanotide as a research peptide. That does not make it equivalent to FDA-approved Vyleesi. It also does not guarantee sterility, accurate concentration, stability, correct identity, or safe use.
The blunt version:
Prescription Vyleesi from a legitimate pharmacy is different from PT-141 sold online as a research peptide.
Is bremelanotide banned in sports?
I did not find an official WADA or USADA source naming bremelanotide as specifically prohibited by name. However, that does not automatically make every product safe for athletes.
The WADA Prohibited List changes over time, and USADA directs athletes to check medications and ingredients through Global DRO or other official anti-doping resources.
For athletes, the practical advice is:
Check Global DRO and current WADA rules before using bremelanotide, Vyleesi, PT-141, or any peptide product. Avoid unapproved online peptide products because contamination, mislabeling, or added banned substances can create anti-doping risk.
Safety and side effects
Bremelanotide has real clinical evidence, but it also has real safety considerations.
Common side effects may include:
- Nausea
- Flushing
- Injection-site reactions
- Headache
- Vomiting
- Cough
- Fatigue
- Hot flashes
- Dizziness
- Nasal congestion
The FDA label highlights several important warnings.
Blood pressure and heart rate
The Vyleesi prescribing information warns about transient increases in blood pressure and reductions in heart rate. It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.
Focal hyperpigmentation
The label warns about focal hyperpigmentation, including darkening of the face, gums, and breasts. This may be more likely in patients with darker skin and with more frequent use.
Nausea
Nausea is one of the most important practical side effects. The FDA label notes nausea as a warning and states that nausea may occur most commonly with the first injection but can also occur after later doses.
Pregnancy considerations
The label advises females of reproductive potential to use effective contraception while taking Vyleesi and discontinue it if pregnancy is suspected.
A serious evaluation of bremelanotide should separate FDA-approved Vyleesi from unapproved PT-141 products sold online.
Bremelanotide vs similar drugs and peptides
| Compound | Category | Main difference |
|---|---|---|
| Bremelanotide | Melanocortin receptor agonist | FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women. |
| PT-141 | Common alternate name for bremelanotide | Often used by online peptide sellers, but research-use PT-141 is not the same as FDA-approved Vyleesi. |
| Flibanserin | Serotonergic medication | Oral daily medication for HSDD, different mechanism and use pattern. |
| Sildenafil | PDE5 inhibitor | Primarily blood-flow mechanism, used for erectile dysfunction and other indications. |
| Melanotan II | Melanocortin-related research peptide | Not the same as FDA-approved Vyleesi and commonly associated with tanning-related online peptide markets. |
| Kisspeptin | Reproductive hormone-related peptide | Different endocrine pathway, not the same indication as Vyleesi. |
The key distinction:
Bremelanotide is not a generic sexual-performance peptide. It is an FDA-approved prescription drug for a specific HSDD population when used as Vyleesi.
Why is bremelanotide sold as “research use only”?
Some online sellers use “research use only” language to sell PT-141 or bremelanotide-like products outside normal prescription-drug channels.
That language is not a trust signal.
A serious reader should understand this distinction:
| Product type | What it means |
|---|---|
| Vyleesi | FDA-approved bremelanotide prescription injection for a specific HSDD indication. |
| PT-141 | Alternate name commonly used for bremelanotide, especially in online peptide markets. |
| Compounded bremelanotide | Not the same as FDA-approved Vyleesi and should be evaluated carefully. |
| Research-use PT-141 | Not an FDA-approved consumer therapeutic product. |
| Online peptide bremelanotide | Higher risk for quality, sterility, dosing, and authenticity problems. |
How to evaluate bremelanotide claims online
| Claim | What to verify |
|---|---|
| “FDA-approved bremelanotide” | Is it actually Vyleesi, or an unapproved PT-141 product using the same active ingredient name? |
| “For men and women” | Vyleesi is not indicated for men. |
| “For postmenopausal women” | Vyleesi is not indicated for postmenopausal women. |
| “Improves sexual performance” | FDA label says Vyleesi is not indicated to enhance sexual performance. |
| “No side effects” | False. Nausea and blood-pressure effects are important known concerns. |
| “Same as Vyleesi” | FDA-approved Vyleesi has specific manufacturing, quality, labeling, and prescribing controls. |
| “Research use only” | This does not mean safe, approved, or appropriate for human use. |
| “PT-141 is just a peptide, not a drug” | Misleading. Bremelanotide is an FDA-approved prescription drug when sold as Vyleesi. |
Bottom line
Bremelanotide is a clinically studied melanocortin receptor agonist and FDA-approved prescription medication when used as Vyleesi for acquired, generalized HSDD in premenopausal women. It has human clinical evidence for improving sexual desire and related distress in that population, but it is not indicated for postmenopausal women, men, or sexual performance enhancement.
The most defensible conclusion is:
Bremelanotide is legitimate as an FDA-approved prescription drug for a narrow use case, but online PT-141 claims often go beyond the evidence. Readers should distinguish FDA-approved Vyleesi from research-use or unapproved peptide products sold online.
FAQ
What is bremelanotide?
Bremelanotide is a melanocortin receptor agonist peptide sold as Vyleesi, an FDA-approved prescription injection for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
What is PT-141?
PT-141 is another name commonly used for bremelanotide. Online sellers often use the PT-141 name for research-use peptide products, but those products are not the same as FDA-approved Vyleesi.
Is bremelanotide FDA-approved?
Yes. Bremelanotide is FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women.
Is bremelanotide for men?
No. Vyleesi is not indicated for men. Claims about PT-141 for men are not the same as the FDA-approved indication.
Is bremelanotide for postmenopausal women?
No. Vyleesi is not indicated for postmenopausal women.
Does bremelanotide improve sexual performance?
Vyleesi is not indicated to enhance sexual performance. It is approved for a specific low-desire disorder in premenopausal women.
Is bremelanotide safe?
Bremelanotide is FDA-approved for a specific use, but it is not risk-free. Important safety concerns include nausea, transient blood-pressure increases, heart-rate reduction, focal hyperpigmentation, and use in patients for whom it is not indicated.
What are the common side effects of bremelanotide?
Common side effects include nausea, flushing, injection-site reactions, headache, vomiting, cough, fatigue, hot flashes, dizziness, and nasal congestion.
Is bremelanotide banned in sports?
I did not find an official WADA or USADA source naming bremelanotide as specifically prohibited by name. Athletes should still check Global DRO and current WADA rules before use, especially because unapproved peptide products can be mislabeled or contaminated.
What is the biggest risk with bremelanotide?
The biggest risks are using it in the wrong population, ignoring blood-pressure and cardiovascular warnings, and confusing FDA-approved Vyleesi with unapproved PT-141 products sold online.
Sources
- FDA: Vyleesi Prescribing Information
- FDA: Vyleesi Approval Package
- PubMed: Bremelanotide First Approval
- PubMed: Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder
- PubMed: Long-Term Safety and Efficacy of Bremelanotide
- PubMed: Bremelanotide for Hypoactive Sexual Desire Disorder Critical Review
- MedlinePlus: Bremelanotide Injection
- WADA: Prohibited List
- USADA: Prohibited List and Global DRO Guidance
Frequently asked questions
What is bremelanotide?
Bremelanotide is a melanocortin receptor agonist peptide sold as Vyleesi, an FDA-approved prescription injection for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
What is PT-141?
PT-141 is another name commonly used for bremelanotide. Online sellers often use the PT-141 name for research-use peptide products, but those products are not the same as FDA-approved Vyleesi.
Is bremelanotide FDA-approved?
Yes. Bremelanotide is FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women.
Is bremelanotide for men?
No. Vyleesi is not indicated for men. Claims about PT-141 for men are not the same as the FDA-approved indication.
Is bremelanotide safe?
Bremelanotide is FDA-approved for a specific use, but it is not risk-free. Important safety concerns include nausea, transient blood-pressure increases, heart-rate reduction, focal hyperpigmentation, and use in patients for whom it is not indicated.
Is bremelanotide banned in sports?
No official WADA or USADA source was found here naming bremelanotide as specifically prohibited by name. Athletes should still check Global DRO and current WADA rules before use.
Sources
- [1]FDA: Vyleesi Prescribing Information
Prescribing Information
- [2]FDA: Vyleesi Approval Package
Regulatory
- [3]PubMed: Bremelanotide First Approval
Clinical Summary
- [4]
- [5]
- [6]
- [7]MedlinePlus: Bremelanotide Injection
Medical Reference
- [8]WADA: Prohibited List
Anti Doping
- [9]
Last updated May 9, 2026